PL3720442T3 - Hamowanie mutanta idh-1 - Google Patents

Hamowanie mutanta idh-1

Info

Publication number
PL3720442T3
PL3720442T3 PL19728271.8T PL19728271T PL3720442T3 PL 3720442 T3 PL3720442 T3 PL 3720442T3 PL 19728271 T PL19728271 T PL 19728271T PL 3720442 T3 PL3720442 T3 PL 3720442T3
Authority
PL
Poland
Prior art keywords
idh
mutant
inhibition
Prior art date
Application number
PL19728271.8T
Other languages
English (en)
Inventor
Patrick F. Kelly
Alan Collis
Jeff Davis
Duncan Walker
Susan Ashwell
Blythe THOMSON
Lu WEI
Original Assignee
Forma Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics, Inc. filed Critical Forma Therapeutics, Inc.
Publication of PL3720442T3 publication Critical patent/PL3720442T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PL19728271.8T 2018-05-16 2019-05-16 Hamowanie mutanta idh-1 PL3720442T3 (pl)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201862672462P 2018-05-16 2018-05-16
US201862672461P 2018-05-16 2018-05-16
US201862680562P 2018-06-04 2018-06-04
US201862680560P 2018-06-04 2018-06-04
US201862680571P 2018-06-04 2018-06-04
US201862680566P 2018-06-04 2018-06-04
US201862692598P 2018-06-29 2018-06-29
US201862692604P 2018-06-29 2018-06-29
US201862692605P 2018-06-29 2018-06-29
US201862692601P 2018-06-29 2018-06-29
US201862692591P 2018-06-29 2018-06-29
US201862773562P 2018-11-30 2018-11-30
US201962798684P 2019-01-30 2019-01-30
US201962798681P 2019-01-30 2019-01-30
US201962798690P 2019-01-30 2019-01-30
US201962798687P 2019-01-30 2019-01-30
US201962798677P 2019-01-30 2019-01-30
US201962812367P 2019-03-01 2019-03-01
PCT/US2019/032747 WO2019222553A1 (en) 2018-05-16 2019-05-16 Inhibiting mutant idh-1

Publications (1)

Publication Number Publication Date
PL3720442T3 true PL3720442T3 (pl) 2023-05-29

Family

ID=66691055

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19728271.8T PL3720442T3 (pl) 2018-05-16 2019-05-16 Hamowanie mutanta idh-1

Country Status (15)

Country Link
US (4) US20210196701A1 (pl)
EP (2) EP3720442B1 (pl)
DK (1) DK3720442T3 (pl)
ES (1) ES2941079T3 (pl)
FI (1) FI3720442T3 (pl)
HR (1) HRP20230168T1 (pl)
HU (1) HUE061331T2 (pl)
LT (1) LT3720442T (pl)
MD (1) MD3720442T2 (pl)
PL (1) PL3720442T3 (pl)
PT (1) PT3720442T (pl)
RS (1) RS64069B1 (pl)
SI (1) SI3720442T1 (pl)
SM (1) SMT202300073T1 (pl)
WO (1) WO2019222553A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
WO2020232381A1 (en) * 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) * 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
MX2022011846A (es) * 2020-03-23 2023-01-04 Lilly Co Eli Metodo para el tratamiento de sujetos resistentes al inhibidor idh1.
AU2021242260B2 (en) * 2020-03-23 2023-12-14 Eli Lilly And Company Combination therapy with a mutant IDH inhibitor
CA3186786A1 (en) * 2020-07-20 2022-01-27 David Michael HYMAN Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
WO2023141087A1 (en) * 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
WO2003106452A2 (en) 2002-06-12 2003-12-24 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US7699767B2 (en) 2002-07-31 2010-04-20 Arryx, Inc. Multiple laminar flow-based particle and cellular separation with laser steering
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2005122942A1 (en) 2004-06-08 2005-12-29 Neil Hamilton Luebke Dental and medical instruments comprising titanium
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
EP2687608B1 (en) 2005-06-08 2017-02-08 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
WO2008131547A1 (en) 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
US8685660B2 (en) 2008-09-03 2014-04-01 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
EP2253716A1 (en) 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor
CA2764785C (en) 2009-06-08 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
EP2552444B1 (en) 2010-04-01 2018-10-10 Council of Scientific & Industrial Research NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
US10640893B2 (en) 2010-09-23 2020-05-05 Invista North America S.A.R.L. Flame retardant fibers, yarns, and fabrics made therefrom
US9695400B2 (en) 2010-10-22 2017-07-04 Duke University Homozygous and heterozygous IDH1 gene-defective human astrocytoma cell lines
US8469749B2 (en) 2010-12-17 2013-06-25 Research In Motion Limited Two-part jack socket for a portable electronic device
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2691391A4 (en) 2011-03-29 2014-09-10 Broad Inst Inc COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
KR102097343B1 (ko) 2011-12-21 2020-04-07 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 RAL GTPases를 타겟으로 하는 항암용 화합물 및 이의 사용방법
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
ES2698625T3 (es) 2012-01-19 2019-02-05 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
EP2634259A1 (en) 2012-03-01 2013-09-04 Deutsches Krebsforschungszentrum Means and methods for the determination of (D)-2-hydroxyglutarate (D2HG)
US8882892B2 (en) 2013-02-04 2014-11-11 Nordson Corporation Powder coating system having powder recovery cyclone with hinged lower section
MX2015012822A (es) 2013-03-14 2016-05-31 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
WO2014184272A2 (en) 2013-05-14 2014-11-20 Medizinische Hochschule Hannover Means and methods for treating cancer
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
PE20170143A1 (es) 2014-02-11 2017-03-19 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HUE062424T2 (hu) 2014-09-19 2023-11-28 Forma Therapeutics Inc Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok
WO2016044787A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
ES2905564T3 (es) 2014-12-22 2022-04-11 Us Health Inhibidores mutantes de IDH1 útiles para tratar el cáncer
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10407419B2 (en) 2015-04-21 2019-09-10 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
MA43374A (fr) 2015-12-04 2018-10-10 Agios Pharmaceuticals Inc Méthodes de traitement de tumeurs malignes
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
JP6682043B2 (ja) 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体ｉｄｈ１阻害剤
JP6987798B2 (ja) 2016-06-22 2022-01-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 癌の治療に変異体ｉｄｈ１阻害剤として有用なチアゾール誘導体
JP6793836B2 (ja) 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体ｉｄｈ１およびｉｄｈ２阻害剤としての７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物
WO2019032747A1 (en) 2017-08-08 2019-02-14 Aviat U.S., Inc. TRAFFIC MANAGEMENT FOR VARIABLE BANDWIDTH NETWORKS USING AN RSVP
WO2019032744A1 (en) 2017-08-11 2019-02-14 Panacea Pharmaceticals Inc. HAAH AND MMP-9 AS COMPLEMENTARY CANCER BIOMARKERS AND METASTASE PREDICTORS WHEN COMBINING THEM
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante

Also Published As

Publication number Publication date
EP3720442B1 (en) 2022-12-28
EP4215197A1 (en) 2023-07-26
MD3720442T2 (ro) 2023-09-30
US11576906B2 (en) 2023-02-14
PT3720442T (pt) 2023-03-13
US20210196701A1 (en) 2021-07-01
DK3720442T3 (da) 2023-03-27
US20200108060A1 (en) 2020-04-09
US20190350919A1 (en) 2019-11-21
SMT202300073T1 (it) 2023-05-12
RS64069B1 (sr) 2023-04-28
EP3720442A1 (en) 2020-10-14
HRP20230168T1 (hr) 2023-05-12
US11376246B2 (en) 2022-07-05
US20260060975A1 (en) 2026-03-05
FI3720442T3 (fi) 2023-03-17
LT3720442T (lt) 2023-04-25
ES2941079T3 (es) 2023-05-16
HUE061331T2 (hu) 2023-06-28
WO2019222553A1 (en) 2019-11-21
SI3720442T1 (sl) 2023-06-30

Similar Documents

Publication Publication Date Title
HUE061331T2 (hu) Mutáns IDH-1 gátlása
IL268852A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
MA52739A (fr) Endonucléases cpf1 mutantes
EP3824778A4 (en) SHOWERHEAD
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3745005A4 (en) FITTING
DOS2019000134S (es) Ornamentacion
DOS2019000137S (es) Ornamentación
EP3870179A4 (en) USP7 ESCAPEMENT
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3424868A4 (en) EXPANSION / CONTRACTION MECHANISM
IL284374A (en) Methods of producing ustekinumab
DOS2019000135S (es) Ornamentación
EP3738603A4 (en) NTCP INHIBITOR
DOS2019000136S (es) Ornamentacion
DOS2019000138S (es) Ornamentacion
DOS2019000133S (es) Ornamentación
IL276107A (en) Crystalline forms of psoorstam
EP3936017A4 (en) Bathtub
DK3899336T3 (da) Vvs-armatur
DOS2019000161S (es) Ornamentación
IL281409A (en) Musk inhibition
EP3962486A4 (en) ESCAPEMENT OF USP36
EP3996650C0 (en) BATHTUB
SG11202101817UA (en) Methods of inhibition